Search for: "Daubert v. Merrell Dow Pharmaceuticals, Inc." Results 1 - 20 of 249
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
5 Apr 2021, 5:00 am by Anjelica Cappellino, J.D.
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993), it upended decades of prior case law interpretation of what it means to be an expert. [read post]
1 Oct 2020, 5:00 am by William Sinclair
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993), the Frye test was the predominant standard for the admissibility of scientific evidence in state and federal courts. [read post]
7 Sep 2020, 11:33 am by Stuart Kaplow
Merrell Dow Pharmaceuticals, Inc., the Supreme Court held that Federal Rule of Evidence superseded Frye’s general acceptance test. [read post]
29 Jun 2020, 12:41 pm by Jim Robinson
Merrell Dow Pharmaceuticals Inc., 509 U.S. 579 (1993), and the testimony is helpful to the trier of fact to understand the evidence through specialized, scientific, or technical expertise. [read post]
13 May 2020, 2:03 am by Schachtman
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579, 592 n.10 (1993). [3]  Id., citing Bourjaily v. [read post]
11 May 2020, 1:09 am by Schachtman
That was the tradition that stood in active need of reform when Daubert was decided in 1993. [read post]
8 May 2020, 3:47 am by Schachtman
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993). [2]  Frye v. [read post]
18 Feb 2020, 5:00 am by Anjelica Cappellino
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993) or Frye v. [read post]
13 Feb 2020, 9:00 am
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993), and thus should not have been admitted nor relied upon. [read post]
23 Jan 2020, 10:37 pm by Schachtman
The phosphodiesterases 5 inhibitor medications (PDE5i) seem to arouse the litigation propensities of the lawsuit industry. [read post]
31 Oct 2019, 5:00 am by Anjelica Cappellino
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993) will consider a non-exhaustive list of factors such as the expert’s methodology and reliability. [read post]